Branchburg, NJ, United States of America

Li-An Xu

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Bristol-Myers Squibb Compnay. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Li-An Xu. Retrieved from https://idiyas.com/inventor/li-an-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Li-An Xu

Introduction

Li-An Xu is a notable inventor based in Branchburg, NJ (US). He has made significant contributions to the field of medical science, particularly in the treatment of diseases related to Interferon gamma inducible protein 10 (IP-10). His innovative approach has led to the development of a unique method for administering anti-IP-10 antibodies.

Latest Patents

Li-An Xu holds 1 patent for his invention titled "IP-10 antibody dosage escalation regimens." This patent outlines a method for treating IP-10-related diseases by administering a predetermined dosage of an anti-IP-10 antibody. The process involves detecting the antibody levels in the subject and adjusting the dosage accordingly to ensure effective treatment.

Career Highlights

Li-An Xu is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and innovations. His work focuses on developing therapies that can significantly improve patient outcomes in the realm of immunology.

Collaborations

Li-An Xu collaborates with talented professionals in his field, including Allison Y Luo and Wendy L Trigona. These collaborations enhance the research and development efforts at Bristol-Myers Squibb Company.

Conclusion

Li-An Xu's contributions to the field of medical science through his innovative patent demonstrate his commitment to improving healthcare solutions. His work continues to pave the way for advancements in the treatment of IP-10-related diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…